Activating the GIP(glucose-dependent insulinotropic polypeptide) receptors has a huge impact on decreasing food intake and increasing energy expenditure
Takada N, Takasugi M, Nonaka Y, Kamiya T, Takemura K, Satoh J, et al
The FDA is clear on this point
We also provide Smallest Detectable Differences (SDD) to support interpretation at the individual level
GLP-1 receptor agonists, once primarily prescribed for Type 2 Diabetes, have evolved into a multi-billion-dollar therapeutic category reshaping obesity treatment, cardiovascular care, metabolic health, and potentially even neurological disorders
Tendon injuries have also appeared in some patients with obesity